NCT00964236View on ClinicalTrials.gov

The Effects of Kuvan on Functional Brain Connectivity in Individuals With Phenylketonuria (PKU)

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2011

Conditions
Phenylketonuria
Interventions
DRUG

Sapropterin

Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.

Trial Locations (1)

65211

University of Missouri, Columbia

Sponsors

Collaborators (1)

BioMarin Pharmaceutical
All Listed Sponsors
collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

University of Missouri-Columbia

OTHER